Abstract
Objective To explore potential applications of the rapid antibody test for COVID-19 screening, in comparison to RT-PCR, for emergency obstetric and gynecological procedures, and medical personnel in the Department of Obstetrics and Gynecology.
Methods A cross-sectional study was conducted in expected 290 participants: 230 patients and 60 medical staff, during the four-month national COVID-19 outbreak period (Aug – Sep 2020, and Dec 2020 - Jan 2021). All participants underwent both rapid antibody tests and RT-PCR (at admission for patients).
Results A total of 270 participants completed the study. Fever and URI symptoms were present in 6/210 patients (2.8%) while one patient (0.5%) had a history of traveling to a high-risk area. However, only two (1%) asymptomatic patients had positive IgM results. Concerning the medical personnel, 10% fell into the ‘patient under investigation (PUI)’ category. 4/60 (6.7%) IgM positive was observed in the staff cohort in which 3/4 came from non-PUI participants. Neither participant had RT-PCR positive demonstrating a 1.9% total false positive rate.
Conclusion Rapid point-of-care antibody test can be used to screen either a pregnant coming for delivery, a patient who requires urgent/emergency operative procedures, or medical personnel, at least in the defined lower-prevalence COVID-19 situation.
Trial registration This study was approved by the Institutional Review Board of Srinakharinwirot University (IRB SWUEC119/2563F) and was registered at the Thai Clinical Trials Registry (TCTR20210613001).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Thai Clinical Trials Registry: TCTR20210613001
Clinical Protocols
https://www.thaiclinicaltrials.org/
Funding Statement
The study received full financial support from the Health System Research Institute (Thai government agencies), Thailand.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Srinakharinwirot University (IRB SWUEC119/2563F).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Synopsis: The article describes the application of the rapid COVID-19 antibody test kit to screen both patients (admitted for operation/procedure) and medical personnel in O&G department.
Data Availability
All data relevant to the study are included in the article. De-identified data of this study could be shared upon request.
